Journal article
Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery
International journal of pharmaceutics, v 414(1), pp 161-170
2011
PMID: 21609756
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Ultrasound contrast agents are destroyed with focused ultrasound, resulting in drug loaded polymer fragments less than 400
nm in diameter capable of escaping the leaky vasculature of a tumor and providing a sustained release of drug.
A polymer ultrasound contrast agent (UCA) developed in our lab has been shown to greatly reduce in size when exposed to ultrasound, resulting in nanoparticles less than 400
nm in diameter capable of escaping the leaky vasculature of a tumor to provide a sustained release of drug. Previous studies with the hydrophilic drug doxorubicin (DOX) demonstrated enhanced drug delivery to tumors when triggered with ultrasound. However the therapeutic potential has been limited due to the relatively low payload of DOX. This study compares the effects of loading the hydrophobic drug paclitaxel (PTX) on the agent's acoustic properties, drug payload, tumoricidal activity, and the ability to deliver drugs through 400
nm pores. A maximum payload of 129.46
±
1.80
μg PTX/mg UCA (encapsulation efficiency 71.92
±
0.99%) was achieved, 20 times greater than the maximum payload of DOX (6.2
μg/mg), while maintaining the acoustic properties. In vitro, the tumoricidal activity of paclitaxel loaded UCA exposed to ultrasound was significantly greater than controls not exposed to ultrasound (
p
<
0.0016). This study has shown that PTX loaded UCA triggered with focused ultrasound have the potential to provide a targeted and sustained delivery of drug to tumors.
Metrics
Details
- Title
- Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery
- Creators
- Michael C Cochran - School of Biomedical Engineering Science and Health Systems, Drexel University, Philadelphia, PA 19104, United StatesJohn Eisenbrey - School of Biomedical Engineering Science and Health Systems, Drexel University, Philadelphia, PA 19104, United StatesRichard O Ouma - School of Biomedical Engineering Science and Health Systems, Drexel University, Philadelphia, PA 19104, United StatesMichael Soulen - Division of Interventional Radiology, University of Pennsylvania, PA, United StatesMargaret A Wheatley - School of Biomedical Engineering Science and Health Systems, Drexel University, Philadelphia, PA 19104, United States
- Publication Details
- International journal of pharmaceutics, v 414(1), pp 161-170
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- School of Biomedical Engineering, Science, and Health Systems
- Web of Science ID
- WOS:000292795500021
- Scopus ID
- 2-s2.0-79959760764
- Other Identifier
- 991014878152604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Pharmacology & Pharmacy